Dang Y - Search Results

1

The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.

Phan-Lai V, Dang Y, Gad E, Childs J, Disis ML. Phan-Lai V, et al. Among authors: dang y. Clin Cancer Res. 2016 May 1;22(9):2207-16. doi: 10.1158/1078-0432.CCR-15-2273. Epub 2015 Dec 9. Clin Cancer Res. 2016. PMID: 26660518 Free PMC article.

2

Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.

Knutson KL, Almand B, Dang Y, Disis ML. Knutson KL, et al. Among authors: dang y. Cancer Res. 2004 Feb 1;64(3):1146-51. doi: 10.1158/0008-5472.can-03-0173. Cancer Res. 2004. PMID: 14871850

3

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.

Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. Knutson KL, et al. Among authors: dang y. J Immunol. 2006 Jul 1;177(1):84-91. doi: 10.4049/jimmunol.177.1.84. J Immunol. 2006. PMID: 16785502

4

Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Dang Y, et al. Clin Cancer Res. 2007 Mar 15;13(6):1883-91. doi: 10.1158/1078-0432.CCR-06-2083. Clin Cancer Res. 2007. PMID: 17363545

5

Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.

Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML. Park KH, et al. Among authors: dang y. Cancer Res. 2008 Oct 15;68(20):8400-9. doi: 10.1158/0008-5472.CAN-07-5891. Cancer Res. 2008. PMID: 18922913 Free PMC article.

6

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG. Disis ML, et al. Among authors: dang y. J Clin Oncol. 2009 Oct 1;27(28):4685-92. doi: 10.1200/JCO.2008.20.6789. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720923 Free PMC article. Clinical Trial.

7

Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.

Dang Y, Disis ML. Dang Y, et al. Ann N Y Acad Sci. 2009 Sep;1174:81-7. doi: 10.1111/j.1749-6632.2009.04937.x. Ann N Y Acad Sci. 2009. PMID: 19769740

8

Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.

Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, Dang Y, Martzen M, Standish LJ, Disis ML. Lu H, et al. Among authors: dang y. Clin Cancer Res. 2011 Jan 1;17(1):67-76. doi: 10.1158/1078-0432.CCR-10-1763. Epub 2010 Nov 10. Clin Cancer Res. 2011. PMID: 21068144 Free PMC article.

9

ELISpot for measuring human immune responses to vaccines.

Slota M, Lim JB, Dang Y, Disis ML. Slota M, et al. Among authors: dang y. Expert Rev Vaccines. 2011 Mar;10(3):299-306. doi: 10.1586/erv.10.169. Expert Rev Vaccines. 2011. PMID: 21434798 Free PMC article. Review.

10

Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.

Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, Disis ML. Dang Y, et al. Clin Cancer Res. 2012 Jun 1;18(11):3122-31. doi: 10.1158/1078-0432.CCR-12-0113. Epub 2012 Apr 17. Clin Cancer Res. 2012. PMID: 22510348 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,052 results

Search Page

Filters